Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Allison Joyce / AP
A new study found targeted probiotics — strains of beneficial bacteria — can reduce sepsis and other potentially life-threatening conditions in newborns, per The Atlantic.
- The study: In the largest trial of its kind, 4,557 Indian newborns were treated for just one week with a specially-developed "synbiotic," a probiotic strain boosted with a sugar, designed to take root in the infant gut.
- By the numbers: The researchers calculated that their probiotic strain should reduce the risk of sepsis, which kills hundreds of thousands of newborns each year, by 25-50%. The study also saw significant and "completely unexpected" reductions in bacterial infections and pneumonia in treated newborns.
- Why it matters: The treatment is a cheap, easily replicated way to ensure the health of newborns and reduce the usage of antibiotics in the developing world. Indeed, the trial was so successful that it was stopped early because it was considered unethical to prevent children from receiving the treatment.